AEROVIA-201 / TCP-201 — Localized Neutrophil Elastase Modulation

Program Code: SCF-CF-S11-0001

Development Status: Hit-to-Lead Optimization Framework

Objective:

Advance the Stage 10 lead-series architecture toward candidate nomination by establishing decision criteria for hit validation, SAR maturation, ADME optimization, and preclinical lead selection.

IMPORTANT SCIENTIFIC BOUNDARY

Stage 11 normally requires:

• Experimental hit data
• Biochemical screening data
• Cellular assay results
• ADME data
• Toxicology observations

Since no experimental dataset currently exists, this stage can only establish the optimization framework and candidate-selection architecture.

No validated lead compound can be nominated without laboratory evidence.

I. HIT-TO-LEAD STRATEGY

Development Funnel

Virtual Hit Pool
      ↓
Biochemical Hits
      ↓
Cellular Hits
      ↓
Validated Leads
      ↓
Optimized Leads
      ↓
Preclinical Candidate

II. HIT TRIAGE FRAMEWORK

Tier 1 Criteria

Biological Activity

Requirements:

• Measurable elastase modulation
• Reproducible activity
• Concentration-response relationship

Tier 2 Criteria

Selectivity

Required Panel:

Comparator

Proteinase 3

Cathepsin G

Trypsin

Chymotrypsin

Goal:

Preferential neutrophil elastase activity.

Tier 3 Criteria

Cellular Compatibility

Endpoints:

• epithelial viability
• barrier integrity
• inflammatory biomarkers

III. SERIES A OPTIMIZATION PLAN

AEROVIA-201A

Synthetic Elastase Regulatory Platform

Optimization Priorities

Priority 1

Protease selectivity

Priority 2

Pulmonary exposure

Priority 3

Safety margin

Priority 4

Manufacturability

Success Profile

IV. SERIES B OPTIMIZATION PLAN

Taspine-Inspired Program

Development Goal

Structural preservation and ECM protection.

Evaluation Domains

• inflammatory modulation
• ECM preservation
• epithelial recovery

Risk

Complex chemistry and PK variability.

V. SERIES C OPTIMIZATION PLAN

Iridoid-Inspired Program

Development Goal

Cytokine harmonization.

Evaluation Domains

• IL-8 modulation
• TNF modulation
• NF-κB signaling

Risk

Metabolic instability.

VI. SAR DEVELOPMENT MATRIX

Desired SAR Trends

VII. ADME OPTIMIZATION GATES

Discovery ADME Profile

VIII. PRECLINICAL SCREENING CASCADE

Stage A

Biochemical Evaluation

Endpoints:

• elastase activity
• selectivity profile

Stage B

Cellular Evaluation

Models:

• CF epithelial cells
• air-liquid interface cultures

Endpoints:

• viability
• IL-8
• MMP-9
• barrier integrity

Stage C

Functional Models

Endpoints:

• ECM preservation
• elastin degradation
• inflammatory modulation

Stage D

Pulmonary PK

Endpoints:

• lung concentration
• lung/plasma ratio
• residence time

IX. LEAD SCORING ALGORITHM

Weighted Ranking Matrix

Candidate Advancement Threshold

Minimum composite score:

≥80/100

X. PRECLINICAL CANDIDATE NOMINATION FRAMEWORK

Candidate Requirements

Pharmacology

• Strong target engagement

Safety

• Acceptable pulmonary tolerability

PK

• High lung exposure

Formulation

• DPI compatible

Development

• Manufacturable

XI. PROVISIONAL LEAD SERIES RANKING

Based on current non-experimental evidence:

XII. SCF PRECLINICAL CANDIDATE PROFILE

Desired Candidate Characteristics

Therapeutic Profile

• inhaled
• lung localized
• chronic-use compatible

Biological Profile

• partial elastase modulation
• host-defense preservation
• ECM preservation

PK Profile

• high lung/plasma ratio
• low systemic exposure

Safety Profile

• minimal airway irritation
• minimal systemic toxicity

XIII. STAGE 11 DECISION GATE

STAGE 11 OUTCOME

CONDITIONAL ADVANCEMENT TO STAGE 12

STAGE 12 — PRECLINICAL CANDIDATE NOMINATION & DEVELOPMENT CANDIDATE PACKAGE

Stage 12 Deliverables:

1. Development Candidate Selection
2. Candidate Nomination Report
3. Preclinical Development Plan
4. IND-Enabling Study Blueprint
5. CMC Candidate Package
6. Clinical Translation Package
7. Regulatory Interaction Package

Advancement Condition

Actual progression beyond Stage 11 requires experimental screening data. Without biochemical, cellular, PK, and safety data, Stage 12 remains a planning exercise rather than a true candidate nomination.

MASTER REGISTRY INDEX

SCF-CF-S11-0001 — Hit-to-Lead Optimization & Candidate Selection Framework

SCF-CF-API-201 — AEROVIA-201 Pulmonary Neutrophil Elastase Modulator

SCF-HITDISC-0001 — Hit Discovery Framework

SCF-SAR-0001 — Structure–Activity Relationship Framework

SCF-ADME-0001 — ADME Optimization Framework

SCF-PKPD-0001 — Pharmacokinetic & Pharmacodynamic Framework

SCF-SEF-MD-0001 — Synergistic Evaluation Framework

SCF-FDA-IND-0001 — Translational Development Framework